FI20030026A0 - Menetelmä substituoitujen imidatsolijohdannaisten valmistamiseksi ja menetelmässä käytettäviä välituotteita - Google Patents

Menetelmä substituoitujen imidatsolijohdannaisten valmistamiseksi ja menetelmässä käytettäviä välituotteita

Info

Publication number
FI20030026A0
FI20030026A0 FI20030026A FI20030026A FI20030026A0 FI 20030026 A0 FI20030026 A0 FI 20030026A0 FI 20030026 A FI20030026 A FI 20030026A FI 20030026 A FI20030026 A FI 20030026A FI 20030026 A0 FI20030026 A0 FI 20030026A0
Authority
FI
Finland
Prior art keywords
sub
preparation
imidazole derivatives
substituted imidazole
intermediates used
Prior art date
Application number
FI20030026A
Other languages
English (en)
Swedish (sv)
Other versions
FI20030026A (fi
FI116292B (fi
Original Assignee
Juvantia Pharma Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juvantia Pharma Ltd Oy filed Critical Juvantia Pharma Ltd Oy
Publication of FI20030026A0 publication Critical patent/FI20030026A0/fi
Priority to FI20030026A priority Critical patent/FI116292B/fi
Priority to CNB2004800019799A priority patent/CN100339368C/zh
Priority to EP04700707A priority patent/EP1581504B1/en
Priority to DE602004020050T priority patent/DE602004020050D1/de
Priority to AT04700707T priority patent/ATE425972T1/de
Priority to PT04700707T priority patent/PT1581504E/pt
Priority to CA2511969A priority patent/CA2511969C/en
Priority to MXPA05007217A priority patent/MXPA05007217A/es
Priority to AU2004203941A priority patent/AU2004203941B2/en
Priority to NZ539831A priority patent/NZ539831A/en
Priority to PCT/FI2004/000004 priority patent/WO2004063168A1/en
Priority to US10/537,177 priority patent/US7223871B2/en
Priority to JP2006500148A priority patent/JP4592680B2/ja
Priority to PL378179A priority patent/PL213564B1/pl
Priority to KR1020057012682A priority patent/KR101079065B1/ko
Priority to ES04700707T priority patent/ES2322463T3/es
Priority to RU2005125044/04A priority patent/RU2329253C2/ru
Priority to BR0406676-6A priority patent/BRPI0406676A/pt
Priority to DK04700707T priority patent/DK1581504T3/da
Publication of FI20030026A publication Critical patent/FI20030026A/fi
Priority to IL168452A priority patent/IL168452A/en
Priority to NO20053712A priority patent/NO330965B1/no
Application granted granted Critical
Publication of FI116292B publication Critical patent/FI116292B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
FI20030026A 2003-01-08 2003-01-08 Menetelmä substituoitujen imidatsolijohdannaisten valmistamiseksi ja menetelmässä käytettäviä välituotteita FI116292B (fi)

Priority Applications (21)

Application Number Priority Date Filing Date Title
FI20030026A FI116292B (fi) 2003-01-08 2003-01-08 Menetelmä substituoitujen imidatsolijohdannaisten valmistamiseksi ja menetelmässä käytettäviä välituotteita
PCT/FI2004/000004 WO2004063168A1 (en) 2003-01-08 2004-01-08 Process for preparing substituted imidazole derivatives and intermediates used in the process
JP2006500148A JP4592680B2 (ja) 2003-01-08 2004-01-08 置換イミダゾール誘導体の製造方法およびその製造方法で使用される中間体
DE602004020050T DE602004020050D1 (de) 2003-01-08 2004-01-08 Verfahren zur herstellung substituierter imidazolderivate und in dem verfahren verwendete zwischenprodukte
AT04700707T ATE425972T1 (de) 2003-01-08 2004-01-08 Verfahren zur herstellung substituierter imidazolderivate und in dem verfahren verwendete zwischenprodukte
PT04700707T PT1581504E (pt) 2003-01-08 2004-01-08 Processo de preparação de derivados de imidazole substituídos e intermediários utilizados no processo
CA2511969A CA2511969C (en) 2003-01-08 2004-01-08 Process for preparing substituted imidazole derivatives and intermediates used in the process
MXPA05007217A MXPA05007217A (es) 2003-01-08 2004-01-08 Proceso para la preparacion de derivados de imidazol sustituidos y los productos intermedios usados en este proceso.
AU2004203941A AU2004203941B2 (en) 2003-01-08 2004-01-08 Process for preparing substituted imidazole derivatives and intermediates used in the process
NZ539831A NZ539831A (en) 2003-01-08 2004-01-08 Process for preparing substituted imidazole derivatives and intermediates used in the process
CNB2004800019799A CN100339368C (zh) 2003-01-08 2004-01-08 取代的咪唑衍生物的制备方法及该方法中使用的中间体
US10/537,177 US7223871B2 (en) 2003-01-08 2004-01-08 Process for preparing substituted imidazole derivatives and intermediates used in the process
EP04700707A EP1581504B1 (en) 2003-01-08 2004-01-08 Process for preparing substituted imidazole derivatives and intermediates used in the process
PL378179A PL213564B1 (pl) 2003-01-08 2004-01-08 Sposób wytwarzania podstawionych pochodnych imidazolu i zwiazki posrednie stosowane w sposobie
KR1020057012682A KR101079065B1 (ko) 2003-01-08 2004-01-08 치환된 이미다졸 유도체를 제조하기 위한 방법 및 공정에서사용된 중간체
ES04700707T ES2322463T3 (es) 2003-01-08 2004-01-08 Preocedimiento para preparar derivados de imidazol sustituidos y productos intermedios utilizados en el procedimiento.
RU2005125044/04A RU2329253C2 (ru) 2003-01-08 2004-01-08 Способ получения производных замещенного имидазола и промежуточные соединения, используемые в этом способе
BR0406676-6A BRPI0406676A (pt) 2003-01-08 2004-01-08 Processo para preparar derivados de imidazol substituìdo, para preparar um composto e composto resultante
DK04700707T DK1581504T3 (da) 2003-01-08 2004-01-08 Fremgangsmåde til fremstilling af subsituterede imidazolderivater og intermediater anvendt i fremgangsmåden
IL168452A IL168452A (en) 2003-01-08 2005-05-05 Process for preparing substituted imidazole derivatives and intermediates used in the process
NO20053712A NO330965B1 (no) 2003-01-08 2005-08-01 Fremgangsmate for fremstilling av substituerte imidazolderivater, mellomprodukter anvendt i fremgangsmaten samt fremgangsmate for fremstilling av mellomprodukt

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20030026A FI116292B (fi) 2003-01-08 2003-01-08 Menetelmä substituoitujen imidatsolijohdannaisten valmistamiseksi ja menetelmässä käytettäviä välituotteita
FI20030026 2003-01-08

Publications (3)

Publication Number Publication Date
FI20030026A0 true FI20030026A0 (fi) 2003-01-08
FI20030026A FI20030026A (fi) 2004-07-09
FI116292B FI116292B (fi) 2005-10-31

Family

ID=8565279

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20030026A FI116292B (fi) 2003-01-08 2003-01-08 Menetelmä substituoitujen imidatsolijohdannaisten valmistamiseksi ja menetelmässä käytettäviä välituotteita

Country Status (21)

Country Link
US (1) US7223871B2 (fi)
EP (1) EP1581504B1 (fi)
JP (1) JP4592680B2 (fi)
KR (1) KR101079065B1 (fi)
CN (1) CN100339368C (fi)
AT (1) ATE425972T1 (fi)
AU (1) AU2004203941B2 (fi)
BR (1) BRPI0406676A (fi)
CA (1) CA2511969C (fi)
DE (1) DE602004020050D1 (fi)
DK (1) DK1581504T3 (fi)
ES (1) ES2322463T3 (fi)
FI (1) FI116292B (fi)
IL (1) IL168452A (fi)
MX (1) MXPA05007217A (fi)
NO (1) NO330965B1 (fi)
NZ (1) NZ539831A (fi)
PL (1) PL213564B1 (fi)
PT (1) PT1581504E (fi)
RU (1) RU2329253C2 (fi)
WO (1) WO2004063168A1 (fi)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008003553A1 (es) * 2007-12-05 2009-11-27 Grindeks Jsc Proceso para preparar atipamezol o clorhidrato de 5-(2-etil-2,3-dihidro-1h-inden-2-il)-1h-imidazol: y loa compuestos intermediarios considerados en el proceso
EP2456749B1 (en) * 2009-07-24 2016-03-30 DSM Pharma Chemicals Regensburg GmbH Indane derivatives for use as intermediates
EP2459540A4 (en) * 2009-07-31 2012-12-19 Reddys Lab Ltd Dr PREPARATION OF FIPAMEZOLE
EP2502917A1 (en) * 2011-03-17 2012-09-26 Santhera Pharmaceuticals (Schweiz) AG Solid state crystalline forms of 4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-1H-imidazole

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI833794A0 (fi) * 1983-10-18 1983-10-18 Farmos Oy Substituerade 2-merkapto-imidazoler
GB2167408B (en) * 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
AU7040500A (en) 1999-09-06 2001-04-10 Lg Chem Investment Ltd. Process for preparing a 1-substituted 5-hydroxymethyl imidazole
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds

Also Published As

Publication number Publication date
AU2004203941A1 (en) 2004-07-29
KR101079065B1 (ko) 2011-11-02
EP1581504B1 (en) 2009-03-18
US20060025465A1 (en) 2006-02-02
RU2005125044A (ru) 2006-01-20
NO20053712L (no) 2005-08-01
PL378179A1 (pl) 2006-03-06
DK1581504T3 (da) 2009-06-29
JP4592680B2 (ja) 2010-12-01
FI20030026A (fi) 2004-07-09
JP2006515349A (ja) 2006-05-25
CA2511969C (en) 2011-10-11
CN100339368C (zh) 2007-09-26
FI116292B (fi) 2005-10-31
BRPI0406676A (pt) 2005-12-20
PT1581504E (pt) 2009-05-26
MXPA05007217A (es) 2005-09-12
CA2511969A1 (en) 2004-07-29
EP1581504A1 (en) 2005-10-05
AU2004203941B2 (en) 2009-08-06
US7223871B2 (en) 2007-05-29
ATE425972T1 (de) 2009-04-15
IL168452A (en) 2009-07-20
PL213564B1 (pl) 2013-03-29
RU2329253C2 (ru) 2008-07-20
CN1723202A (zh) 2006-01-18
KR20050091065A (ko) 2005-09-14
NZ539831A (en) 2007-11-30
WO2004063168A1 (en) 2004-07-29
DE602004020050D1 (de) 2009-04-30
ES2322463T3 (es) 2009-06-22
NO330965B1 (no) 2011-08-29

Similar Documents

Publication Publication Date Title
HK1167658A1 (en) Composition for the preparation of 17-vinyl- triflates as intermediates 17--
WO2007041167A3 (en) Process for production of delta-9-tetrahydrocannabinol
DK1877384T3 (da) Fremgangsmåde til fremstilling af eventuelt 2-substituerede 1,6-dihydro-6-oxo-4-pyrimidincarboxylsyrer
ATE441627T1 (de) Verfahren zur herstellung von valsartan
WO2009047313A3 (en) Method of producing 2' -deoxy-5-azacytidine (decitabine)
NO20023126L (no) Fremgangsmåte for fremstilling av citalopram
NO20053712L (no) Fremgangsmate for fremstilling av substituerte imidazolderivater og mellomprodukter anvendt i fremgangsmaten
ATE428693T1 (de) Prostaglandinsynthese
MEP18708A (en) Process for the production of beraprost and its salts
ATE496907T1 (de) Verfahren zur herstellung von cilostazol
DK0717042T3 (da) Fremgangsmåde til fremstilling af 1-(4,5-dihydro-2-thiazolyl)-3-azetidin-thiol-derivater
RS20060157A (en) Method for the manufacture of thip
MXPA03011647A (es) Procedimiento de resolucion para el acido ( r ) - (-) - 2-hidroxi - 2- (2 - clorofenil) acetico.
DK1631533T3 (da) Hidtil ukendt fremgangsmåde til stereoselektiv reduktion af beta-ketoestre
DE60114889D1 (de) Verfahren zur herstellung von fluconazole und kristallmodifikationen davon
NO20022690L (no) Nye strukturelle analoger av Vitamin D
EA200501135A1 (ru) Способы получения алкалоидов хиназолина
RS20050824A (en) Novel intermediate for the preparation of therapeutically active imidazopyridines
DE50107619D1 (de) Verfahren zur herstellung von 4-brom-anilin-derivaten
NO20055925L (no) Ny fremgangsmate for fremstilling av melagatran
DE69815906D1 (de) Verfahren zur Herstellung von Chloroacetylaminothiazoleaceticsäure Derivate
JO3022B1 (ar) طريقة لانتاج 2'-دياوكسي-5-ازاسيتيدين (ديسيتابين)

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 116292

Country of ref document: FI

MM Patent lapsed